Concussion and TBI biomarker tools mature
Plasma GFAP and UCH-L1 assays for concussion and traumatic brain injury are establishing routine emergency-department use.
Plasma biomarker testing for concussion and traumatic brain injury (GFAP, UCH-L1, NFL) is moving from research into routine emergency-department use. The clinical case is rule-out: a negative biomarker result safely avoids CT imaging in selected patients. The infrastructure question is whether the assays land in routine ED workflow or stay confined to academic centres.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
DiagnosisBiomarkersInfrastructure
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.